BAO PHARMA-B(02659): KJ101 received clinical trial approval for new indications.

BAO PHARMA-B (02659) announced that the company's independently developed and China's leading recombinant human plasminogen KJ101, developed through synthetic biology, has been approved by the China National Medical Products Administration for clinical trials in China for the dissolution and removal of gastric mucus during gastroscopy. Plasminogen is a protease that can rapidly break down proteins, liquefy pus, and necrotic tissue. With its specific protein hydrolysis activity, it can effectively break down accumulated fibrous proteins, collagen protein fragments, and other protein fragments in chronic or acute wounds. Plasminogen is widely used in departments such as respiratory, surgery, otorhinolaryngology, obstetrics and gynecology, pediatrics, stomatology, ophthalmology, dermatology, gastroenterology, and proctology, especially in the removal of necrotic tissue, promoting wound healing, and improving gastroscopic visibility. KJ101 is China's leading recombinant human plasminogen developed through the company's synthetic biology, aimed at replacing animal-derived products comprehensively. Based on the company's unique recombinant yeast fermentation technology, KJ101 provides a pure, safer, more scalable alternative solution with high expression levels. KJ101 has core advantages such as high purity, no risk of animal-derived virus contamination, and no allergenicity. Its wide range of raw material sources is not affected by fluctuations in the upstream livestock industry, with minimal batch-to-batch variability, and no impact from changes in raw material quality, ensuring good clinical safety. For indications such as burns, trauma, surgical incisions, pressure ulcers, and diabetic foot ulcers, the company obtained IND approval for KJ101 from the National Medical Products Administration in February 2025 and initiated its Phase II clinical trial (CTR20252263) in July 2025.